急性磷化铝中毒的胰岛素-血糖正常疗法:一项随机临床试验
该随机临床试验纳入108例急性磷化铝中毒患者,干预组在标准治疗(去甲肾上腺素和支持治疗)基础上接受胰岛素-血糖正常疗法,对照组接受标准治疗加安慰剂。结果显示干预组病死率64.8%,对照组96.3%(P<0.001);干预组升压药中位用量7 mg vs 对照组26 mg(P=0.006),需插管比例61.1% vs 81.5%(P=0.019);入科后6小时中位收缩压、舒张压和平均动脉压分别为80 mmHg、55 mmHg、65 mmHg vs 对照组20 mmHg、10 mmHg、13 mmHg(P<0.001),碳酸氢盐和乳酸浓度亦改善。作者认为胰岛素-血糖正常疗法似乎是安全有效的治疗选择,仅用升压药治疗与极差结局相关。
要点
- 急性磷化铝中毒:胰岛素-血糖正常疗法组病死率64.8%,对照组96.3%(P<0.001)。
- 干预组升压药中位用量7 mg vs 对照组26 mg(P=0.006),需插管比例61.1% vs 81.5%(P=0.019)。
- 入科后6小时中位收缩压、舒张压、平均动脉压:干预组80 mmHg、55 mmHg、65 mmHg,对照组20 mmHg、10 mmHg、13 mmHg(P<0.001)。
- 干预组碳酸氢盐和乳酸浓度较对照组改善。
- 作者认为胰岛素-血糖正常疗法似乎是安全有效的治疗选择;仅用升压药治疗与极差结局相关。
适用人群与场景
- 急性磷化铝中毒患者,共108例随机分配至两组。
处置流程与药物剂量
- 干预组:在标准治疗(去甲肾上腺素和支持治疗)基础上接受胰岛素-血糖正常疗法。
- 对照组:标准治疗加安慰剂。
研究设计与关键结果
- 研究类型:随机临床试验,前瞻性注册于泛非临床试验注册中心(PACTR202008534546951),共108例患者随机分配至两组。
- 主要结局:干预组病死率64.8%,对照组96.3%(P<0.001)。
- 次要结局:干预组升压药中位用量7 mg vs 对照组26 mg(P=0.006);需插管比例61.1% vs 对照组81.5%(P=0.019)。
- 血压:入科后6小时中位收缩压、舒张压、平均动脉压干预组分别为80 mmHg、55 mmHg、65 mmHg,对照组分别为20 mmHg、10 mmHg、13 mmHg(P<0.001)。
- 实验室指标:干预组碳酸氢盐和乳酸浓度较对照组改善。
- 基线参数:两组相似。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,胰岛素-血糖正常疗法似乎是急性磷化铝中毒患者安全有效的治疗选择。
- 作者指出,仅用升压药治疗与急性磷化铝中毒的极差结局相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Aluminum phosphide is a pesticide that is used in developing countries. Aluminum phosphide poisoning has a high mortality rate and there is no known antidote. This study aimed to evaluate the safety and efficacy of insulin-euglycemia therapy in the management of patients with acute aluminum phosphide poisoning.Methods: This trial was prospectively registered in the Pan African Clinical Trials Registry (PACTR202008534546951). A total of 108 patients were randomly allocated to two groups. The intervention group received insulin-euglycemia therapy in addition to standard treatment (norepinephrine and supportive care); the control group received standard treatment plus placebo. The main outcome measures were survival, blood pressure, and laboratory investigations.Results: The two groups had similar baseline parameters. Insulin-euglycemia therapy was associated with a significant reduction in mortality compared with that in the control group (64.8 percent and 96.3 percent, respectively; P value <0.001). Patients randomized to insulin-euglycemia also required lower doses of vasopressors (median was 7 mg versus 26 mg in control group; P value 0.006) and fewer patients needed intubation (61.1 percent versus 81.5 percent in the control group; P value 0.019). Insulin-euglycemia therapy significantly improved blood pressure (systolic, diastolic, and mean arterial pressure) (median at 6h post-admission was 80 mmHg, 55 mmHg and 65 mmHg compared with 20 mmHg, 10 mmHg and 13 mmHg in the control group respectively; P value <0.001) and bicarbonate and lactate concentrations.Conclusion: Insulin-euglycemia therapy appears to be a safe and effective treatment option for patients with aluminum phosphide poisoning. Vasopressor only therapy was associated with very poor outcomes in acute aluminum phosphide poisoning.
参考来源
- Adel B, Elgharbawy NM, Shahin MM, et al. Insulin-euglycemia therapy in acute aluminum phosphide poisoning: a randomized clinical trial. Clin Toxicol (Phila). 2024. PMID: 38096041. doi:10.1080/15563650.2023.2279495
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。